share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4:持股變動聲明-高管 Bruno Julianne
美股sec公告 ·  05/24 16:20
Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG的首席運營官朱麗安·布魯諾於2024年5月23日參與了與該公司股票的交易。但是,有關行動類型、地位、所涉股票數量、股票性質、交易價格和交易後股票總價值的詳細信息尚未披露。這些信息對於投資者了解內部人士的行爲對其投資決策的影響至關重要。
CRISPR Therapeutics AG的首席運營官朱麗安·布魯諾於2024年5月23日參與了與該公司股票的交易。但是,有關行動類型、地位、所涉股票數量、股票性質、交易價格和交易後股票總價值的詳細信息尚未披露。這些信息對於投資者了解內部人士的行爲對其投資決策的影響至關重要。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息